CSF3 and lymphoma: Meanwhile, patients treated for lymphomas or other hematologic diseases (listed in Table 1, n = 95) were chemo-mobilized in all cases, and either received cyclophosphamide-etoposide (CE) or rituximab-cytarabine (R-AraC) in addition to G-CSF.